Cardiac Biomarkers Market Size is expected to cross USD 4236.02 Million by 2025 at a CAGR of 16.36%.
Cardiac biomarkers are protein molecules released into the bloodstream from heart muscle damaged by a blocked artery. These enzymes are measured to have an idea of how much muscle damage has been done. These biomarkers are specially used to help diagnosis, evaluate, and monitor patients with suspected acute coronary syndrome (ACS).
The increasing prevalence of cardiovascular diseases is expected to drive the growth of the global Cardiac Biomarkers Diagnostics Market Trends. Out of the 17 million premature deaths due to noncommunicable diseases in 2015, 82% were in low- and middle-income countries, and 37% were caused by cardiovascular diseases.
Tests for cardiac biomarkers are used to diagnose acute coronary syndrome (ACS) and cardiac ischemia, conditions associated with insufficient blood flow to the heart. These biomarkers are also helpful in determining a person's risk of these conditions and also helps monitor and manage someone with ACS and cardiac ischemia.
Troponin T and I, CK-MB, and myoglobins are most commonly in the evaluation of acute coronary syndrome. Out of this troponin T and I are the markers of choice for detecting the heart damage. However, other cardiac biomarkers are less specific for heart and may be elevated in other conditions like severe muscle injury, liver disease, and kidney disease.
The increasing incidence of cardiac diseases and related conditions are strongly motivating market players to introduce new efficient technologies in the market.
High prevalence of cardiac disorders and increasing participation of market players are actively facilitating the growth of the cardiac biomarkers market. In September 2019, Abbott received FDA clearance for ARCHITECT STAT High Sensitivity Troponin-I blood test. This troponin diagnostic test will be used to detect heart attacks faster and more accurately than contemporary troponin tests.
- High prevalence of raised blood pressure: Raised blood pressure is the leading risk factor for cardiovascular disease. The prevalence of this troponin T blood pressure in adults aged 18 years and over was around 24.1% in men and 20.1% in women in 2015
- Increasing adoption of outsourcing services
- Growing technological advancements:
- High spending by the pharmaceutical industry
- The increasing popularity of POC cardiac testing kits
- Increasing affordability for advanced cardiac treatments
- Chances of false diagnosis of myocardial infarction
- High cost of the procedure
- Presence of other efficient methods for the diagnosis of cardiovascular diseases
Cardiac Biomarkers Market Segmentation
- Myocardial muscle Creatine Kinase (CK-MB): CK-MB has been the gold standard for detecting myocardial necrosis. After myocardial infarction, elevated CK-MB levels appear within 3- 8 hours, peaking within 9-30 hours and levels return to normal after 48- 72 hours
- Troponins (T and I): The most important characteristic of this biomarker is its apparent absolute cardiac specificity. Among patients with acute coronary syndromes, troponins level has been reported to provide prognostic information useful for the early identification of patients with an elevated risk of unstable angina progressing to AMI and death
- Myoglobin: Myoglobin is a low molecular weight heme protein is rapidly released into the circulation and is the first marker to exhibit raising levels after myocardial infarction
- Brain Natriuretic Peptide (BNPs) or NT-proBNP: This biomarker is secreted primarily by the ventricular myocardium in response to wall stress. It is a very useful prognostic indicator in acute coronary syndrome
- Ischemia Modified Albumin (IMA): This novel marker is produced when circulating serum albumin contacts ischemic heart tissues. IMA can be measured by the Albumin Cobalt Binding assay that is based on IMA's ability to bind to cobalt.
By Location of Testing
- Point of Care Testing: Point of care testing expected to witness significant growth in the forecast period due to its increasing popularity
- Laboratory Testing: Laboratory testing segment dominated the global cardiac biomarkers market. Increasing demand for cardiovascular disease diagnostics is boosting the revenue of this segment
- Acute Coronary Syndrome: This segment holds the largest share owing to the increasing cases of this condition. It is a medical emergency that requires prompt diagnosis and care.
- Congestive Heart Failure: It is a chronic progressive condition that affects the pumping power of your heart muscles
- Myocardial Infarction: Approximately 1.5 million cases of myocardial infarction occur annually in the US region.
- Atherosclerosis: Atherosclerosis is a disease in which plaque builds up inside your arteries. Cardiac troponins are used to assess the prognosis of patients presenting with atherosclerosis
- Americas: The largest regional market. High prevalence of cardiac diseases is strongly expanding the US cardiac biomarkers market. As per the data suggested by the Centers for Disease Control and Prevention (CDC), around 610,000 people die of heart disease in the US every year. Also, coronary heart disease (CHD) is the most common type of heart disease, killing over 370,000 people annually.
- Europe: Europe has some of the best healthcare services in the world, and rising participation of market players is strongly boosting the Europe cardiac biomarkers market. For instance, in October 2019, Novartis received FDA approval for Entresto for the treatment of symptomatic heart failure in pediatric patients aged one year and older.
- Asia-Pacific: The fastest-growing regional market for Cardiac Biomarkers, Asia-Pacific, has the world’s largest population and fast-developing healthcare industry. Rising affordability for the advanced cardiac treatments and increasing disposable incomes are strongly impacting the growth of the Cardiac Biomarkers market in the region
- Middle East & Africa: The Middle East & Africa has been primarily bifurcated into two regions—the Middle East and Africa. The presence of favorable government initiatives and recent healthcare reforms and developing healthcare infrastructure in the Middle East is expected to augment the market growth over the forecast period.
- Abbott Laboratories (US)
- ACS Biomarker (The Netherlands)
- BD (Becton, Dickinson and Company) (US)
- bioMérieux SA (France)
- Bio-Rad Laboratories, Inc. (US)
- Danaher Corporation (US)
- Hoffmann-La Roche Ltd (Switzerland)
- Johnson and Johnson (US)
- Quidel Corporation (US)
- Randox Laboratories Limited (UK)
- Siemens AG (Germany)
- Thermo Fisher Scientific, Inc. (US)
- Trivitron Healthcare Pvt. Ltd. (India)
- Novartis (Switzerland)
Browse More Report Details @ https://www.marketresearchfuture.com/reports/cardiac-biomarkers-market-8594